ResearcherAsan Medical CenterNo recent work listed
JiHoon Kang
Matched on ORCID iD 0000-0001-7231-5480; OpenAlex author ID A5102811506. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2017: 1 paper · 2018: 1 paper · 2019: 1 paper
Papers 3
- Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammat… First author DOI 10.1007/s10637-018-0681-y↗
- Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Co-author DOI 10.1007/s10637-018-0598-5↗
- Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. First author DOI 10.18632/oncotarget.17940↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kyu‐pyo Kim · 3 shared papers, 2017–2019 · strength 0.22
- Paper Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel pl… DOI 10.1007/s10637-018-0681-y↗
- Paper Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreati… DOI 10.1007/s10637-018-0598-5↗
- Paper Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy co… DOI 10.18632/oncotarget.17940↗
- Baek‐Yeol Ryoo · 3 shared papers, 2017–2019 · strength 0.22
- Paper Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel pl… DOI 10.1007/s10637-018-0681-y↗
- Paper Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreati… DOI 10.1007/s10637-018-0598-5↗
- Paper Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy co… DOI 10.18632/oncotarget.17940↗
- Changhoon Yoo · 3 shared papers, 2017–2019 · strength 0.22
- Paper Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel pl… DOI 10.1007/s10637-018-0681-y↗
- Paper Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreati… DOI 10.1007/s10637-018-0598-5↗
- Paper Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy co… DOI 10.18632/oncotarget.17940↗
- Inhwan Hwang · 2 shared papers, 2018–2019 · strength 0.16
- Paper Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel pl… DOI 10.1007/s10637-018-0681-y↗
- Paper Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreati… DOI 10.1007/s10637-018-0598-5↗
- Ki Byung Song · 2 shared papers, 2017–2018 · strength 0.12
- Paper Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreati… DOI 10.1007/s10637-018-0598-5↗
- Paper Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy co… DOI 10.18632/oncotarget.17940↗
- Do Hyun Park · 2 shared papers, 2017–2018 · strength 0.12
- Paper Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreati… DOI 10.1007/s10637-018-0598-5↗
- Paper Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy co… DOI 10.18632/oncotarget.17940↗
- Dae Wook Hwang · 2 shared papers, 2017–2018 · strength 0.12
- Paper Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreati… DOI 10.1007/s10637-018-0598-5↗
- Paper Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy co… DOI 10.18632/oncotarget.17940↗
- Tae Jun Song · 2 shared papers, 2017–2018 · strength 0.12
- Paper Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreati… DOI 10.1007/s10637-018-0598-5↗
- Paper Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy co… DOI 10.18632/oncotarget.17940↗
- Myung‐Hwan Kim · 2 shared papers, 2017–2018 · strength 0.12
- Paper Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreati… DOI 10.1007/s10637-018-0598-5↗
- Paper Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy co… DOI 10.18632/oncotarget.17940↗
- Dong Wan Seo · 2 shared papers, 2017–2018 · strength 0.12
- Paper Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreati… DOI 10.1007/s10637-018-0598-5↗
- Paper Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy co… DOI 10.18632/oncotarget.17940↗
- Sang Soo Lee · 2 shared papers, 2017–2018 · strength 0.12
- Paper Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreati… DOI 10.1007/s10637-018-0598-5↗
- Paper Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy co… DOI 10.18632/oncotarget.17940↗
- Song Cheol Kim · 2 shared papers, 2017–2018 · strength 0.12
- Paper Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreati… DOI 10.1007/s10637-018-0598-5↗
- Paper Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy co… DOI 10.18632/oncotarget.17940↗
- Sang Hyun Shin · 1 shared paper, 2018 · strength 0.06
- Seung‐Mo Hong · 1 shared paper, 2018 · strength 0.06
- Jin‐hong Park · 1 shared paper, 2017 · strength 0.06
- Jae‐Lyun Lee · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.